AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval for ELAHERE (mirvetuximab soravtansine-gynx), marking a major advancement for patients suffering from this challenging condition. ELAHERE is designed to treat folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or […]
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at treating platinum-resistant recurrent ovarian cancer. This significant regulatory milestone accelerates the drug’s development and potential commercialization, addressing an urgent need for new treatments in this challenging cancer subtype. AVB-S6-500 is […]
